Maze Therapeutics Reports Positive Topline Data From Phase 2 HORIZON Trial Of MZE829; Stock Up 9%

Maze Therapeutics reported positive topline Phase 2 HORIZON data for MZE829, an oral dual‑mechanism APOL1 inhibitor, in patients with broad APOL1‑mediated kidney disease (AMKD). The readout de‑risks the program and could materially enhance the asset’s value and partnering prospects. Expect potential share movement in the single‑digit percentage range for MAZE as investors re‑price the clinical outlook and commercial potential.

Analysis

Maze Therapeutics reported positive topline Phase 2 HORIZON data for MZE829, an oral dual‑mechanism APOL1 inhibitor, in patients with broad APOL1‑mediated kidney disease (AMKD). The readout de‑risks the program and could materially enhance the asset’s value and partnering prospects. Expect potential share movement in the single‑digit percentage range for MAZE as investors re‑price the clinical outlook and commercial potential.